Fulcrum Therapeutics (FULC) Total Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Total Liabilities for 9 consecutive years, with $13.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Liabilities fell 8.33% year-over-year to $13.3 million; the TTM figure through Jun 2026 stood at $13.3 million (down 8.33% YoY), while the FY2025 annual figure was $17.3 million, down 2.26% from the prior year.
• Total Liabilities fell to $13.3 million in Q2 2026 per FULC's latest filing, from $13.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $34.5 million in Q2 2022 and bottomed at $13.3 million in Q2 2026.
• Historically, Total Liabilities has averaged $21.3 million across 5 years, with a median of $21.1 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities grew 27.75% — and 2025, when it declined 29.35%.
• Fulcrum Therapeutics' Total Liabilities stood at $27.7 million in 2022, then retreated by 18.89% to $22.5 million in 2023, then retreated by 21.41% to $17.7 million in 2024, then declined by 2.26% to $17.3 million in 2025, then retreated by 23.31% to $13.3 million in 2026.
• Business Quant data shows FULC's Total Liabilities at $13.3 million in Q2 2026, $13.5 million in Q1 2026, and $17.3 million in Q4 2025.